The Li Lab
Assessing the performance of next-generation sequencing techniques in accurate genome/epigenome/transcriptome profiling and understanding the clinical and functional role of epigenome heterogeneity in the cancer evolution.
Principal Investigator
Location
Connect
Topics
Our research focus
Algorithm development and integrative mining from high-throughput sequencing data to determine how somatic mutations alter the blood cancer epigenome and gene regulation in the context of aging, and lay the foundation for crafting future epigenetic therapeutic and preventative strategies.
-
Featured ArticleOctober 24, 2023Applying AI and machine learning to complex research tasks
JAX researchers are at the forefront of developing and implementing AI-based technologies for a variety of research applications. -
Research HighlightJanuary 12, 2021Few mutations, important difference in cancer cells
JAX Professor Sheng Li, Ph.D., presents a tool, epihet, that automates the epigenetic analysis of AML cells. epihet allows researchers to assess epigenetic differences between cells, identify genomic locations where the differences occur, and associate cellular epigenetic profiles with cancer-related biological function. -
Research HighlightJune 17, 2020New research reveals the role of epigenetic dysfunction in blood cancer
A new discovery by JAX cancer researcher Sheng Li points to the possibility of new lymphoma treatments that would restore the protective effect of TET2 in tumors where it has been mutated. -
Research HighlightOctober 11, 2018Stuck in a dangerous cycle
Paper provides important insight for B-cell lymphomagenesis from mouse models to human disease.
-
Profile StoryNovember 09, 2021Using next-gen technology to explore how aging raises the risk for leukemia
JAX's Sheng Li is exploring how aging raises the risk for leukemia, and works to improve cutting edge tools for data analysis. -
Research HighlightOctober 20, 2020Connecting genetics with epigenetics in acute myeloid leukemia
Acute myeloid leukemia (AML) is an aggressive, difficult-to-treat cancer. Nonetheless, researchers have found that there are not as many genetic mutations associated with AML as with most other cancers. Aberrant epigenetic patterning, on the other hand, is emerging as a hallmark of AML. -
Search MagazineSeptember 04, 2019Computing the etiology of cancer
What if, much like screening through genetic testing, we could learn how to better treat individual patients through their unique epigenetic markers? This is the question that Assistant Professor Sheng Li, Ph.D. tackles in her lab every day.